NCT03832127 - Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2026

Conditions

Myeloma

Interventions

DRUG

18F-Fludarabine

Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma

Trial Locations (7)

RECRUITING

CHU de Caen, Caen

RECRUITING

CHU de Brest, Brest

WITHDRAWN

Centre Eugène Marquis, Rennes

WITHDRAWN

CHU de Rennes, Rennes

RECRUITING

CHU de Tours, Tours

RECRUITING

CHU de Nantes, Nantes

RECRUITING

CHU d'Angers, Angers